FDA-Approved Weight Loss Drugs 2026: New Pills and What’s Next

Looking for the FDA approved weight loss drugs of 2026? So far they are oral Wegovy (semaglutide tablets, approved December 2025), Foundayo (orforglipron, a new weight loss pill approved 1 April 2026) and Wegovy HD (a higher-dose 7.2 mg semaglutide injection, approved 19 March 2026). CagriSema is still under FDA review and retatrutide is still investigational, so neither is available as a prescription product yet.

The obesity-medication landscape is moving quickly. People have more questions about pills versus injections, how medicines differ, and whether a drug in the news is actually available yet.

This guide is US-focused and reflects regulatory information checked on 11 October 2026. Drug status and availability can differ in the UK, EU and other countries.

Oral Wegovy: semaglutide in tablet form

The FDA approved Wegovy tablets in December 2025 for labeled weight-management use in adults, with a cardiovascular risk-reduction indication for a specified population. The tablets contain semaglutide, the active ingredient also found in injectable Wegovy and diabetes-branded Ozempic.

A pill may appeal to people who prefer not to inject, but “oral” does not automatically mean more effective, easier for everyone, less expensive in every plan or suitable for everyone. Follow the product's administration instructions and discuss options with a prescriber.

Foundayo (orforglipron): the new weight loss pill of 2026

The FDA approved Foundayo (orforglipron) on 1 April 2026 for chronic weight management in eligible adults. It is an oral small-molecule GLP-1 receptor agonist. Lilly announced US availability on 9 April 2026.

Foundayo is a different molecule from semaglutide. A useful comparison should cover the approved indication, trial populations and duration, administration instructions, side effects, availability and cost—not just one headline weight-loss percentage. Results from different trials should not be treated as a direct contest.

Wegovy HD: a higher-dose weight loss injection

The FDA approved Wegovy HD, a 7.2 mg semaglutide injection, on 19 March 2026 for a specified adult weight-management population. A higher dose does not mean a person should increase their own dose, and it is not automatically appropriate for everyone using semaglutide.

The current prescribing information and a qualified prescriber's judgment remain the source of truth for eligibility and use.

CagriSema: combination treatment under regulatory review

CagriSema combines cagrilintide, an amylin analogue, with semaglutide. Novo Nordisk announced submission of a US FDA application in December 2025. As of 11 October 2026, the FDA had not approved CagriSema; Novo Nordisk has said it expects a US decision in the fourth quarter of 2026.

A company-reported trial average is not the same as approval, commercial availability or a guarantee about any individual's results.

Retatrutide: exciting trial news, but still investigational

Retatrutide is an investigational triple hormone-receptor agonist acting on GIP, GLP-1 and glucagon pathways. Eli Lilly reported positive Phase 3 results in 2026; the TRIUMPH-1 obesity trial was published in the New England Journal of Medicine in September 2026. Lilly has said it plans to submit a US application in the first quarter of 2027. More detail: Retatrutide in 2026.

That is important news, but retatrutide remained investigational in the sources checked as of 11 October 2026. Do not buy products sold online as retatrutide or “research peptides.” A molecule being studied is not the same as an approved, quality-controlled prescription product being available to consumers.

How to compare trial headlines fairly

Before comparing percentages, check whether trials enrolled people with diabetes, their baseline characteristics, duration, dose escalation, dropout handling and whether the reported number is an on-treatment result or an intention-to-treat result. Company press releases are useful for announcements, but treat their numbers as sponsor-reported until full peer-reviewed results are published.

What should readers do with this news?

A headline about a bigger average result isn't a reason to change treatment on your own. If you have side effects or questions about alternatives, talk to your clinician about whether an approved option fits your goals, history, availability and coverage.

For readers following the pipeline, distinguish four milestones: trial recruitment, trial results, regulator submission and approval. Headlines often compress these into “the next miracle drug,” which isn't accurate.

Common questions

Which weight loss drugs has the FDA approved in 2026?

As of the sources checked on 11 October 2026, the new US approvals are Foundayo (orforglipron), approved 1 April 2026, and Wegovy HD (7.2 mg semaglutide injection), approved 19 March 2026. Wegovy tablets were approved in December 2025 and are the other new option people ask about. CagriSema and retatrutide are not approved.

Is there a new weight loss pill in 2026?

Yes. Foundayo (orforglipron) is an oral small-molecule GLP-1 receptor agonist approved for chronic weight management in eligible adults, with US availability announced on 9 April 2026. Oral Wegovy (semaglutide tablets) is the other pill option. A pill is not automatically more effective, easier or cheaper than an injection, so talk through the choice with a prescriber.

What is the best weight loss injection in 2026?

There is no single “best” injection for everyone. The newest approved option is Wegovy HD, a 7.2 mg semaglutide injection approved for a specified adult weight-management population. A higher dose is not a reason to raise your own dose; the prescribing information and your prescriber decide what fits your history, availability and coverage.

Which GLP-1 medications are approved for weight loss in 2026?

The GLP-1 medicines with new US weight-management approvals are oral Wegovy and Wegovy HD (both semaglutide) and Foundayo (orforglipron). CagriSema, which pairs semaglutide with the amylin analogue cagrilintide, was still under FDA review as of 11 October 2026, with a decision expected in the fourth quarter of 2026.

Is retatrutide FDA approved?

No. Retatrutide is an investigational triple agonist (GIP, GLP-1 and glucagon). Lilly reported positive Phase 3 results in 2026 and plans to submit a US application in the first quarter of 2027. Products sold online as retatrutide or “research peptides” are not approved, quality-controlled prescription medicines.

The takeaway

2026 has brought new US options, including oral Wegovy, Foundayo and higher-dose Wegovy HD, while CagriSema and retatrutide require careful status checking. News is exciting, but approval status, direct comparisons and personal suitability are separate questions.

GLPily can help organize the medication history, weight trends and symptoms you want to discuss with your healthcare team.